INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
17 oct. 2023 08h00 HE
|
INmune Bio, Inc.
An in-depth analysis of MRI gray matter microstructure following treatment with XPro™ shows that the greatest improvement was in the earliest and most affected regions of the AD brain; an effect that...
INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
16 oct. 2023 09h00 HE
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 16, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage...
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
07 sept. 2023 09h00 HE
|
INmune Bio, Inc.
Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s immune system to fight...
INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease
05 sept. 2023 08h00 HE
|
INmune Bio, Inc.
The authorization provides approval for the Company to expand the ongoing Phase 2 trial of XPro™ in patients with early Alzheimer’s disease to the U.K. Boca Raton, Florida, Sept. 05, 2023 ...
INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update
07 août 2023 16h00 HE
|
INmune Bio, Inc.
BOCA RATON, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
01 août 2023 08h00 HE
|
INmune Bio, Inc.
Boca Raton, FL, Aug. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s immune system to fight...
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
31 juil. 2023 08h00 HE
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a...
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
12 juil. 2023 08h00 HE
|
INmune Bio, Inc.
RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies to Improve Health Span by Treating the Chronic Diseases of Aging Boca Raton, Florida, July 12, 2023 ...
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease
11 juil. 2023 08h00 HE
|
INmune Bio, Inc.
Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM ...
INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology
10 juil. 2023 16h00 HE
|
INmune Bio, Inc.
Neutralizing soluble TNF with XPro™ promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses Boca Raton, Florida, July 10, 2023 (GLOBE...